Products INCB059872
INCB059872 Phase 1 Terminated 💤 Quiet Jun 27, 2018 → Jun 25, 2020
About INCB059872 INCB059872 is a phase 1 stage product being developed by Incyte for Relapsed Ewing Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03514407. Target conditions include Relapsed Ewing Sarcoma.
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT03514407 Phase 1 Terminated Jun 27, 2018 Jun 25, 2020 Relapsed Ewing Sarcoma NCT03132324 Phase 1 Terminated Apr 20, 2017 Oct 3, 2018 Sickle Cell Disease
Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 VIP152 + BTKi Vincerx Pharma Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 AC220 Daiichi Sankyo Phase 1 Valemetostat Tosylate Daiichi Sankyo Phase 2 Linsitinib Astellas Pharma Phase 2 AGS67E Astellas Pharma Phase 1 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib Eisai Phase 2 Tazemetostat Eisai Phase 2 Tazemetostat Eisai Phase 1 Eribulin mesylate Eisai Phase 2 ME-401 Kyowa Kirin Phase 1 KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 Kyowa Kirin Phase 1 Mogamulizumab Kyowa Kirin Phase 2 ONO-4685 Ono Pharmaceutical Phase 1 ONO-4685 Ono Pharmaceutical Phase 1 Tirabrutinib + Rituximab + Temozolomide Ono Pharmaceutical Phase 3
Other Products from Incyte